3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
2
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
37
Neoplasms
3
Neoplasm Metastasis
3
Breast Diseases
3
Neoplasms by Site
2
Triple Negative Breast Neoplasms
1
Skin Diseases
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Lobular
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal, Breast
1
Breast Neoplasms, Male
1
Breast Neoplasm Female
1
Breast Cancer Female
1
Advanced Breast Carcinoma
1
Interventions
Carboplatin
25
Paclitaxel
24
pembrolizumab
22
Cyclophosphamide
14
Gemcitabine
10
Capecitabine
10
Doxorubicin
9
Specimen Handling
8
Nivolumab
8
Taxes
7
Magnetic Resonance Spectroscopy
7
sacituzumab govitecan
6
olaparib
6
Cisplatin
6
eribulin
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
capivasertib
4
Epirubicin
4
Docetaxel
4
Biopsy
4
niraparib
3
Vinorelbine
3
Radiation
3
Fulvestrant
3
Blood Specimen Collection
3
trastuzumab deruxtecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Triple Negative Breast Neoplasms
×
Anastrozole
×
Clear all
NCT04556773
2025-12-17
DB-08
AstraZeneca
Phase 1
Active not recruiting
138 enrolled